Histochem Cell Biol (2008) 129:735–749 Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH (2001) Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol 153:283–294 Tao GZ, Toivola DM, Zhong B, Michie SA, Resurreccion EZ, Tamai Y, Taketo MM, Omary MB (2003) Keratin-8 mice have diVerent gallbladder and liver susceptibility to lithogenic diet-in- duced injury. J Cell Sci 116:4629–4638 Tao GZ, Zhou Q, Strnad P, Salemi MR, Lee YM, Omary MB (2005) Human Ran cysteine-112 oxidation by pervanadate regulates its binding to keratins. J Biol Chem 280:12162–12167 Tao GZ, Strnad P, Zhou Q, Kamal A, Zhang L, Madani ND, Kugatha- san S, Brant SR, Cho JH, Omary MB, Duerr RH (2007) Analysis of keratin polypeptides 8 and 19 variants in inXammatory bowel disease. Clin Gastroenterol Hepatol 5:857–864 Tao GZ, Li D, Zhou Q, Toivola D, Strnad P, Sandesara N, Cheung R, Hong A, Omary M (2008) Monitoring of epithelial cell caspase activation via detection of durable keratin fragment formation. J Pathol in press Tarantino G, Conca P, Coppola A, Vecchione R, Di Minno G (2007) Serum concentrations of the tissue polypeptide speciWc antigen in patients suVering from non-alcoholic steatohepatitis. Eur J Clin Invest 37:48–53 Tephly TR, Gibbs AH, Ingall G, De Matteis F (1980) Studies on the mechanism of experimental porphyria and ferrochelatase inhibi- tion produced by 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine. Int J Biochem 12:993–998 Tephly TR, CoVman BL, Ingall G, Ziet-Har MS, GoV HM, Tabba HD, Smith KM (1981) IdentiWcation of N-methylprotoporphyrin IX in livers of untreated mice and mice treated with 3, 5-diethoxycar- bonyl- 1, 4-dihydrocollidine: source of the methyl group. Arch Biochem Biophys 212:120–126 Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB (2004) Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology 40:459–466 Toivola DM, Tao GZ, Habtezion A, Liao J, Omary MB (2005) Cellular integrity plus: organelle-related and protein-targeting functions of intermediate Wlaments. Trends Cell Biol 15:608–617 Vadlamudi RK, Joung I, Strominger JL, Shin J (1996) P62, a phospho- tyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271:20235–20237 Van Eyken P, Sciot R, Callea F, Van der Steen K, Moerman P, Desmet VJ (1988) The development of the intrahepatic bile ducts in man: a keratin-immunohistochemical study. Hepatology 8:1586–1595 Vassy J, Irinopoulou T, Beil M, Rigaut JP (1997) Spatial distribution of cytoskeleton intermediate Wlaments during fetal rat hepatocyte diVerentiation. Microsc Res Tech 39:436–443 Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL (2004) Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14:95–104 749 Villeneuve JP, Pichette V (2004) Cytochrome P450 and liver diseases. Curr Drug Metab 5:273–282 Volkmann X, Cornberg M, Wedemeyer H, Lehner F, Manns MP, Schulze-OsthoV K, Bantel H (2006) Caspase activation is re- quired for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 43:1311–1316 Wang Z, Figueiredo-Pereira ME (2005) Inhibition of sequestosome 1/p62 upregulation prevents aggregation of ubiquitinated proteins induced by prostaglandin J2 without reducing its neurotoxicity. Mol Cell Neurosci 29:222–231 Wick MR (2000) Immunohistology of neuroendocrine and neuroecto- dermal tumors. Semin Diagn Pathol 17:194–203 Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:27–33 Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, Rubinsztein DC (2006) Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 76:89–101 Wöll S, WindoVer R, Leube RE (2007) p38 MAPK-dependent shaping of the keratin cytoskeleton in cultured cells. J Cell Biol 177:795– 807 Wooten MW, Geetha T, Babu JR, Seibenhener ML, Peng J, Cox N, Diaz-Meco MT, Moscat J (2008) Essential role of SQSTM1/p62 in regulating accumulation of K63-ubiquitinated proteins. J Biol Chem 283:6783–6789 Yokoo H, Minick OT, Batti F, Kent G (1972) Morphologic variants of alcoholic hyaline. Am J Pathol 69:25–40 Yokoo H, Harwood TR, Racker D, Arak S (1982) Experimental produc- tion of Mallory bodies in mice by diet containing 3, 5-diethoxycar- bonyl-1, 4-dihydrocollidine. Gastroenterology 83:109–113 Zatloukal K, Fesus L, Denk H, Tarcsa E, Spurej G, Böck G (1992) High amount of -( -glutamyl) lysine cross links in Mallory bod- ies. Lab Invest 66:774–777 Zatloukal K, Stumptner C, Lehner M, Denk H, Baribault H, Eshkind LG, Franke WW (2000) Cytokeratin 8 protects from hepatotoxic- ity, and its ratio to cytokeratin 18 determines the ability of hepa- tocytes to form Mallory bodies. Am J Pathol 156:1263–1274 Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H (2002) P62 is a common component of cytoplasmic inclusions in protein aggre- gation diseases. Am J Pathol 160:255–263 Zatloukal K, Stumptner C, Fuchsbichler A, Fickert P, Lackner C, Trau- ner M, Denk H (2004) The keratin cytoskeleton in liver diseases. J Pathol 204:367–376 Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, Cadrin M, Omary MB (2007) From Mallory to Mallory- Denk bodies: what, how and why? Exp Cell Res 313:2033–2049 Zhou Q, Ji X, Chen L, Greenberg HB, Lu SC, Omary MB (2005) Ker- atin mutation primes mouse liver to oxidative injury. Hepatology 41:517–525 123